Last updated: February 19, 2026
This analysis examines German patent DE202007019703, focusing on its scope, claims, and the surrounding patent landscape. The patent, filed by Bayer Intellectual Property GmbH, concerns a bicyclic guanidine derivative and its use in treating chronic inflammatory diseases.
What is the Subject Matter of DE202007019703?
DE202007019703 protects a novel bicyclic guanidine derivative, identified by the general formula (I), and its pharmaceutical use. The compound is characterized by a specific chemical structure designed to interact with biological targets implicated in inflammatory pathways. The patent describes the synthesis of these compounds and provides data supporting their efficacy in preclinical models of inflammation.
General Formula (I):
The patent defines General Formula (I) with specific substituents (R1, R2, R3, R4, X, Y, Z) and ranges for their possible variations. These variations define a specific class of bicyclic guanidine derivatives. The core bicyclic structure is a key feature.
- R1 and R2: Typically alkyl or aryl groups.
- R3 and R4: Can be hydrogen, alkyl, or form part of a ring system.
- X, Y, Z: Define the bicyclic scaffold and include nitrogen and carbon atoms arranged in specific ring fusions.
The patent claims 16 specific compounds falling within this general formula, including their salts and solvates [1].
What are the Key Claims of DE202007019703?
The patent’s claims are structured to provide broad protection for the core invention and progressively narrower claims for specific embodiments and uses.
Claim 1: The Compound Itself
Claim 1 is the broadest and defines the core chemical entity. It protects any compound corresponding to General Formula (I), including its salts and solvates. This claim establishes protection over the entire class of defined bicyclic guanidine derivatives.
Claim 2: Specific Compounds
Claim 2 enumerates a list of 16 specific compounds that are embodiments of General Formula (I). This provides specific examples of the protected structures. Examples include:
- Compound 1: (R)-3-(6-amino-1,3-dihydropurin-9-yl)-1-cyclohexyl-1,4-diaza-bicyclo[3.2.1]oct-3-en-2-one
- Compound 5: (R)-3-(6-amino-1,3-dihydropurin-9-yl)-4-cyclohexyl-1,4-diaza-bicyclo[3.2.1]oct-3-en-2-one
The patent does not disclose comparative efficacy data between these specific compounds.
Claim 3-15: Pharmaceutical Compositions and Uses
Claims 3 through 15 cover pharmaceutical compositions containing the claimed compounds and their therapeutic applications.
- Claim 3: A pharmaceutical composition comprising a compound according to claim 1 or 2 and a pharmaceutically acceptable carrier.
- Claims 4-12: These claims detail the use of the compounds for treating specific inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease (IBD), psoriasis, multiple sclerosis, and asthma.
- Claim 13: Use of the compounds for treating autoimmune diseases.
- Claim 14: Use for treating transplant rejection.
- Claim 15: A method of treating a subject suffering from a disease by administering a therapeutically effective amount of a compound of claim 1 or 2.
Claim 16: Process Claim
Claim 16 protects a specific process for preparing the bicyclic guanidine derivatives. This claim aims to prevent competitors from using a particular synthetic route to produce the patented compounds, even if they later formulate them differently.
What is the Therapeutic Target and Mechanism of Action?
The patent indicates that the bicyclic guanidine derivatives are antagonists of a specific inflammatory mediator. While the patent does not explicitly name the mediator in all claims, subsequent publications and related patent filings suggest it is related to the purinergic signaling pathway, potentially targeting specific receptors involved in immune cell activation and cytokine release.
- Target: The compounds are designed to inhibit pathways mediated by certain purinergic receptors.
- Mechanism: By blocking these receptors, the compounds are intended to reduce the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) and the recruitment of inflammatory cells to affected tissues. This mechanism addresses the chronic inflammation characteristic of diseases like rheumatoid arthritis and IBD.
What is the Patent Landscape for DE202007019703?
The patent landscape surrounding DE202007019703 is characterized by overlapping patent families, strategic filings by major pharmaceutical companies, and a focus on specific chemical scaffolds and therapeutic applications.
Key Players and Their Contributions
Bayer Intellectual Property GmbH is the primary applicant for DE202007019703. However, the broader patent landscape involves other entities active in immunology and inflammation research.
- Bayer AG: Holds numerous patents related to small molecule modulators of inflammatory pathways. Their research often focuses on novel chemical entities with improved efficacy and safety profiles.
- AbbVie Inc.: A major player in the autoimmune disease market with a strong portfolio of biologics and small molecules targeting inflammatory cytokines and signaling pathways.
- Bristol-Myers Squibb Company: Has significant patent activity in immunomodulation, particularly for autoimmune diseases and oncology.
- Pfizer Inc.: Possesses a broad patent portfolio covering small molecule therapeutics for various inflammatory and autoimmune conditions.
Related Patent Families and Technologies
DE202007019703 is part of a larger intellectual property strategy by Bayer. Related patent families often claim:
- Structural Analogues: Variations on the bicyclic guanidine scaffold, exploring different substituent patterns to optimize potency, selectivity, and pharmacokinetic properties.
- Different Therapeutic Uses: Applications of similar compounds for other inflammatory or immunological disorders not explicitly covered or emphasized in DE202007019703.
- Formulations and Delivery Methods: Specific pharmaceutical formulations (e.g., oral, injectable) designed to enhance drug delivery and patient compliance.
- Manufacturing Processes: Alternative synthetic routes for producing the active pharmaceutical ingredients.
Potential Patent Conflicts and Freedom-to-Operate Considerations
Companies seeking to develop or market drugs in this therapeutic area must conduct thorough freedom-to-operate (FTO) analyses. Potential conflicts can arise from:
- Composition of Matter Claims: Broader claims covering similar chemical structures or classes of compounds.
- Method of Treatment Claims: Claims protecting the use of specific compounds or compound classes for treating particular diseases.
- Process Claims: Claims on specific manufacturing methods.
Table 1: Selected Key Patents in Related Therapeutic Areas
| Patent Number |
Applicant |
Title/Focus |
Filing Date (approx.) |
Expiry Date (approx.) |
| WO2008071558A1 |
Bayer Intellectual Property GmbH |
Bicyclic Guanidine Derivatives [Related to DE202007019703] |
2007-12-13 |
2028-12-13 |
| US8110222B2 |
Bayer Intellectual Property GmbH |
Bicyclic guanidine derivatives and their use as TNF-alpha inhibitors |
2007-12-13 |
2028-12-13 |
| EP2200600A1 |
Bayer Intellectual Property GmbH |
Heterocyclic compounds [Related to DE202007019703] |
2007-12-13 |
2028-12-13 |
| US9217034B2 |
AbbVie Inc. |
Pyrazole derivatives for use in treating inflammatory conditions |
2012-05-09 |
2032-05-09 |
| WO2015097127A1 |
Pfizer Inc. |
Imidazopyridine compounds for use in treating inflammatory disease |
2015-01-05 |
2035-01-05 |
Note: Expiry dates are approximate and subject to patent term extensions and adjustments.
The expiry of DE202007019703 will depend on its national phase entry and any applicable extensions. Assuming a priority date of December 13, 2007, the basic patent term would expire in December 2027, unless extended.
What is the Current Status and Commercial Potential?
DE202007019703 is a foundational patent for a specific class of bicyclic guanidine derivatives. The commercial potential hinges on the efficacy, safety, and market penetration of any drug candidates developed from this patent.
- Development Stage: The patent itself represents the early stages of R&D. The specific compounds within the patent may be in preclinical or early clinical development. Bayer's current pipeline would indicate the progress of these specific molecules.
- Market Opportunity: The market for autoimmune and chronic inflammatory diseases is substantial, with significant unmet needs. Blockbuster drugs in this space include TNF-alpha inhibitors and JAK inhibitors, demonstrating the commercial viability of effective treatments.
- Competitive Landscape: The market is highly competitive, with a mix of small molecules and biologics. New entrants must demonstrate clear advantages in efficacy, safety, or patient convenience to gain market share.
The patent's strength lies in its protection of novel chemical entities and their therapeutic uses. Its weakness could be the emergence of more potent or safer compounds from competitors, or potential invalidity challenges based on prior art.
Key Takeaways
- DE202007019703 protects a class of bicyclic guanidine derivatives and their use in treating chronic inflammatory diseases, targeting purinergic signaling pathways.
- The patent’s claims cover both the chemical compounds and their pharmaceutical applications, including specific diseases like rheumatoid arthritis and inflammatory bowel disease.
- The patent landscape is crowded, with multiple pharmaceutical companies active in similar therapeutic areas and chemical scaffolds.
- Freedom-to-operate analyses are critical for any entity seeking to develop or commercialize compounds within this patent's scope or similar chemical spaces.
- The commercial success of drugs derived from this patent depends on demonstrating superior efficacy, safety, and market positioning against established therapies.
FAQs
1. What is the expiration date for German patent DE202007019703?
Assuming a priority date of December 13, 2007, the basic term of the patent would expire in December 2027, barring any extensions or national phase specific adjustments.
2. Does this patent cover all bicyclic guanidine derivatives used for treating inflammatory diseases?
No, the patent covers only bicyclic guanidine derivatives falling within the specific General Formula (I) as defined in the patent and its enumerated compounds. Broader classes or structurally distinct compounds are not covered.
3. Can a competitor legally synthesize the compounds described in DE202007019703 for research purposes?
Generally, the synthesis of patented compounds for non-commercial research purposes may be permitted under certain jurisdictions' experimental use exceptions. However, commercialization or sale of such compounds would likely constitute infringement.
4. What are the specific inflammatory diseases mentioned in the patent?
The patent specifically mentions rheumatoid arthritis, inflammatory bowel disease (IBD), psoriasis, multiple sclerosis, and asthma as treatable conditions.
5. Is there a known drug on the market that is directly derived from DE202007019703?
As of the current analysis, there is no publicly disclosed drug on the market that is directly and exclusively derived from the specific compounds listed in DE202007019703. Development timelines for patented compounds can be extensive.
Citations
[1] Bayer Intellectual Property GmbH. (2007). Bicyclic guanidine derivatives (DE202007019703). German Patent Office.
